IMPLANT DEVICE FOR EYE DISEASE TO WHICH DRUG DELIVERY MATRIX IS APPLIED

• Main Authors: KO, Kyeonghyeon, RYU, Junoh, KIM, Jiyeon, CHOI, Seung Hyun
• Format: Patent
• Language: English; French; Korean
• Published: 18.01.2024
• Subjects: BANDAGES, DRESSINGS OR ABSORBENT PADS; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, ORSURGICAL ARTICLES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF,TUBULAR STRUCTURES OF THE BODY, E.G. STENTS; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; FILTERS IMPLANTABLE INTO BLOOD VESSELS; FIRST-AID KITS; FOMENTATION; HUMAN NECESSITIES; HYGIENE; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICALARTICLES; MEDICAL OR VETERINARY SCIENCE; METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS INGENERAL; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; PROSTHESES; TREATMENT OR PROTECTION OF EYES OR EARS

An implant device for an eye disease for being injected into an eyeball may comprise: a tube configured to have one end inserted into the anterior chamber of an eyeball and having a cavity to discharge aqueous humor; and a matrix member coupled to the outer surface of the tube and made of a material capable of impregnating and releasing a drug. At least a portion of the matrix member may have a cross section larger than the diameter of the tube. When using the implant device for an eye disease, by loading dexamethasone, mitomycin-C (MMC), 5-fluorouracil (5-FU), triamcinolone (TA), and anti-vascular endothelial growth　factor (VEGF) drugs, and an antifibrotic agent, such as a transforming growth factor (TGF)-beta inhibitor, on the matrix member, the antifibrotic agent is allowed to be released from the matrix member to surrounding tissues after the implant device is inserted, thereby preventing the aqueous humor outlet of the tube from clogging due to fibrosis. Un dispositif d'implant pour une maladie oculaire destiné à être injecté dans un globe oculaire peut comprendre : un tube configuré pour avoir une extrémité insérée dans la chambre antérieure d'un globe oculaire et ayant une cavité pour décharger l'humeur aqueuse ; et un élément matrice couplé à la surface externe du tube et constitué d'un matériau capable d'imprégner et de libérer un médicament. Au moins une partie de l'élément matrice peut avoir une section transversale plus grande que le diamètre du tube. Lors de l'utilisation du dispositif d'implant pour une maladie oculaire, en chargeant de la dexaméthasone, de la mitomycine-C (MMC), du 5-fluorouracile (5-FU), de la triamcinolone (TA), et des médicaments anti-facteur de croissance endothélial vasculaire (VEGF), et un agent antifibrotique, tel qu'un inhibiteur du facteur de croissance transformant (TGF)-beta, sur l'élément matrice, l'agent antifibrotique est autorisé à être libéré de l'élément matrice à des tissus environnants après l'insertion du dispositif d'implant, empêchant ainsi la sortie d'humeur aqueuse du tube de se boucher en raison de la fibrose. 안구 내로 삽입되기 위한 안질환용 임플란트 장치는, 일단이 안구의 전방 내로 삽입되도록 구성되며 안방수의 배출을 위한 중공이 형성된 튜브; 및 상기 튜브의 외부 표면에 결합되며 약제를 함침 및 방출 가능한 재료로 이루어진 매트릭스(matrix) 부재를 포함할 수 있다. 상기 매트릭스 부재의 적어도 일부는 상기 튜브의 직경보다 큰 단면을 가질 수 있다. 상기 안질환용 임플란트 장치를 이용하면, 매트릭스 부재에 덱사메타손(dexamethasone), 마이토마이신-C(mitomycin-C; MMC), 5-플루오로우라실(5-fluorouracil; 5-FU), 트리암시놀론(triamcinolone; TA), 항혈관내피성장인자(anti-VEGF(Vascular Endothelial　Growth　Factor)) 약제, 및 전환성장인자-베타 억제제(TGF(Transforming Growth Factor)-beta inhibitor) 등의 항섬유화제를 탑재하여, 임플란트 장치의 삽입 후 매트릭스 부재로부터 주변 조직에 항섬유화제가 방출되도록 함으로써 튜브의 방수 유출구가 섬유화로 인해 막히는 것을 방지할 수 있다.